-
Featured
New Clues Emerge on Management of Recurrent Nonmuscle Invasive Bladder Cancer After Trimodality Therapy
When nonmuscle invasive bladder cancer develops after trimodality therapy for muscle invasive bladder cancer, salvage radical cystectomy isn't necessarily required, researchers have found.
-
Featured
Modified Paclitaxel Plus Daily Radiation Helps Noncystectomy Candidates
Physicians at Massachusetts General Hospital are in the early stages of testing a novel regimen for patients with muscle-invasive urothelial bladder cancer who are medically unfit for radical cystectomy or platinum-based radiosensitizing chemotherapy.
-
Featured
Orthotopic Neobladder Reconstruction Restores Quality of Life for Female Cystectomy Patients
Orthotopic neobladder reconstruction is becoming the diversion procedure of choice for female cystectomy patients due to recent advances in care for female urology patients.
-
AUA 2019: A Media Roundup
At the 2019 AUA Annual Conference, urologists from Mass General discussed research findings, novel treatment approaches and advances in clinical care, including...
-
Comparative Effectiveness of Bladder-preserving Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer
According to decision analysis modeling by researchers at the Mass General Cancer Center, trimodality therapy with the goal of preserving the bladder is similar to radical cystectomy in terms of survival outcomes. However, trimodal therapy may provide a greater quality of life for patients with muscle-invasive bladder cancer.
-
Five Sessions to See at #AUA2019
The American Urological Association (AUA) is hosting its Annual Meeting in Chicago, IL from May 3-6, 2019. Specialists from the Massachusetts General Hospital Department of Urology will present on leading research and innovative treatment approaches. Mass General doctors will participate in over 20 different sessions covering the full spectrum of urologic care, including bladder, prostate, urologic oncology and more.
Bladder contributors
-
Chin-Lee Wu, MD, PhD
Associate Pathologist, Massachusetts General Hospital, Associate Professor of Pathology, Harvard Medical School, Director, Genitourinary Pathology Services
Recent Article
New Target Discovered for Prostate Cancer Immunotherapy -
Douglas Middleton Dahl, MD
Chief, Division of Urologic Oncology, Director of Robotic Surgery, Associate Professor, Harvard Medical School
Recent Article
AUA 2019: A Media Roundup
-
Jason A. Efstathiou, MD, Dphil
Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic
Recent Article
Comparative Effectiveness of Bladder-preserving Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer -
Marc Dror Michaelson, MD, PhD
Clinical Director, Genitourinary Cancer Center
Recent Article
Modified Paclitaxel Plus Daily Radiation Helps Noncystectomy Candidates -
Matthew F. Wszolek, MD
Assistant in Urology, Massachusetts General Hospital, Instructor in Surgery, Harvard Medical School
Recent Article
New Clues Emerge on Management of Recurrent Nonmuscle Invasive Bladder Cancer After Trimodality Therapy
-
Michael L. Blute, MD
Chief, Department of Urology, Walter S. Kerr, Jr., Professor of Surgery, Harvard Medical School
Recent Article
Orthotopic Neobladder Reconstruction Restores Quality of Life for Female Cystectomy Patients
-
William Shipley, MD
Andres Soriano Distinguished Professor of Radiation Oncology, Harvard Medical School
Recent Article
Alternative Chemoradiation Regimen of Trimodal Therapy Found Effective for Muscle-invasive Bladder Cancer
Urology Care at Mass General
The Department of Urology at Massachusetts General Hospital offers sophisticated, compassionate care and the most innovative treatments for patients with any type of urological condition.Resource Links
